[TNXP] Tonix Pharmaceuticals Holding Corp.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.48 Change: -0.02 (-3.23%)
Ext. hours: Change: 0 (0%)

chart TNXP

Refresh chart

Strongest Trends Summary For TNXP

TNXP is in the medium-term down -22% below S&P in 2 months and down -83% in 7 months. In the long-term down -99% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Tonix Pharmaceuticals Holding Corp., a development stage specialty pharmaceutical company, focuses on the identification and development of pharmaceutical products for the disorders of central nervous system. The company?s lead product candidate, TNX-102 sublingual tablet, is a dosage formulation of cyclobenzaprine for the treatment of fibromyalgia and post-traumatic stress disorder. It also has a pipeline of various other product candidates, including TNX-201, which is a treatment for certain types of episodic tension-type headache; and TNX-301 that is indicated for the treatment of alcohol abuse and dependence. The company was founded in 2007 and is headquartered in New York, New York.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-53.14% ROE-56.49% ROI
Current Ratio17.06 Quick Ratio Long Term Debt/Equity Debt Ratio0.06
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities29.05 M Cash From Operating Activities Gross Profit
Net Profit-9.05 M Operating Profit-9.7 M Total Assets60.47 M Total Current Assets59.99 M
Total Current Liabilities3.52 M Total Debt Total Liabilities3.58 M Total Revenue
Technical Data
High 52 week13 Low 52 week1.35 Last close1.9 Last change-1.04%
RSI31.82 Average true range0.09 Beta0.89 Volume907.47 K
Simple moving average 20 days-2.84% Simple moving average 50 days-9.4% Simple moving average 200 days-62.87%
Performance Data
Performance Week-2.06% Performance Month0% Performance Quart-60.39% Performance Half-84.03%
Performance Year-43.79% Performance Year-to-date-13.64% Volatility daily2.51% Volatility weekly5.6%
Volatility monthly11.49% Volatility yearly39.79% Relative Volume1010.85% Average Volume849.68 K
New High New Low

News

2019-03-18 08:00:00 | Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights

2019-03-12 07:30:00 | Tonix Pharmaceuticals to Participate at Upcoming Investor Conferences

2019-03-11 09:35:00 | Four Healthcare Stocks Making Moves on Monday

2019-03-11 07:00:00 | Tonix Pharmaceuticals Enrolls First Participant in the “RECOVERY” Study -- a New Phase 3 Trial of Tonmya® for the Treatment of Posttraumatic Stress Disorder

2019-03-08 13:35:00 | Four Healthcare Stocks Surpassing Investor Expectations

2019-03-07 16:15:00 | Tonix Pharmaceuticals Announces New European Use Patent for TNX-601

2019-03-01 17:41:04 | Tonix Pharmaceuticals Provides Update on Tonmya® for the Treatment of Posttraumatic Stress Disorder

2019-03-01 16:00:00 | Tonix Pharmaceuticals Announces Share Repurchase Program

2019-02-19 16:30:00 | Tonix Pharmaceuticals Announces New Board Member, James Treco

2019-02-06 12:17:14 | How Many Insiders Bought Tonix Pharmaceuticals Holding Corp. NASDAQ:TNXP Shares?

2019-02-04 08:00:00 | Tonix Pharmaceuticals to Present at BIO CEO & Investor Conference

2019-01-03 09:45:00 | TNXP: Additional Details Revealed for Phase 3 Trial of TNX-102 SL in PTSD Starting in 1Q19…

2019-01-02 07:00:00 | Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion

2018-12-18 07:00:00 | Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement

2018-12-11 16:00:00 | Tonix Pharmaceuticals Announces Closing of $15,000,000 Public Offering

2018-12-07 13:37:17 | Nano Cap News: Why Tonix Pharmaceuticals TNXP Stock Is Moving Today

2018-12-07 10:35:33 | Tonix Pharmaceuticals Prices $15,000,000 Public Offering

2018-12-03 07:00:00 | Tonix Pharmaceuticals Prepares for Phase III Trial for Tonmya, Analysts Review and Target

2018-11-29 07:00:00 | Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes

2018-11-27 07:00:00 | Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split

2018-11-21 07:35:00 | Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO — Research Highlights Growth, Revenue, and Consolidated Results

2018-11-19 09:45:00 | TNXP: Ready to Initiate Phase 3 Trial of TNX-102 SL in PTSD in 1Q19…

2018-11-09 07:53:23 | Tonix: 3Q Earnings Snapshot

2018-11-09 07:30:00 | Tonix Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights

2018-11-07 07:00:00 | Tonix Pharmaceuticals Announces New Patent Coverage Protecting Tonmya®

2018-11-06 07:00:00 | Tonix Pharmaceuticals Presented Results and Retrospective Analyses of Phase 3 P301 “HONOR” Study in Poster Presentation at CNS Summit 2018

2018-11-01 08:00:00 | Today’s Research Reports on Stocks to Watch: Tonix Pharmaceuticals and ACADIA Pharmaceuticals

2018-11-01 07:00:00 | Tonix Pharmaceuticals to Present at BIO-Europe International Partnering Conference

2018-10-31 10:05:00 | Healthcare Market Growth Could Fuel These Stocks

2018-10-31 07:00:00 | Tonix Pharmaceuticals Announces Innovative Design in Next Phase 3 Study of Tonmya® for PTSD, Following FDA Meeting

2018-10-29 07:00:00 | Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in Poster Presentations at CNS Summit 2018

2018-10-23 07:00:00 | Tonix Pharmaceuticals to Present at the Dawson James Securities Small Cap Growth Conference

2018-10-04 08:00:00 | Today’s Research Reports on Stocks to Watch: Tonix Pharmaceuticals and Vital Therapies

2018-09-26 13:30:00 | Tonix Pharmaceuticals to Present at the MicroCap Conference

2018-09-20 07:00:00 | Tonix Pharmaceuticals to Present at Sidoti & Company Fall 2018 Investor Conference

2018-09-07 07:00:00 | Tonix Pharmaceuticals Announces New Board Member, Oye Olukotun, M.D.

2018-08-30 07:00:00 | Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences

2018-08-27 15:45:00 | TNXP: Retrospective Analyses from HONOR and AtEase Trials Presented…

2018-08-22 16:01:00 | Tonix Pharmaceuticals Announces Director Stepping Down

2018-08-21 09:20:39 | Benzinga Pro's 5 Stocks To Watch Today

2018-08-21 07:00:00 | Tonix Pharmaceuticals Presents Results and Retrospective Analyses of Two Double-Blind, Randomized Placebo-Controlled 12-Week Studies of Tonmya® in Military-Related PTSD at the 2018 Military Health System Research Symposium

2018-08-15 11:46:35 | Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in a Poster Presentation at the 2018 Military Health System Research Symposium

2018-08-13 07:07:26 | Tonix: 2Q Earnings Snapshot

2018-08-13 07:00:00 | Tonix Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights

2018-08-09 12:00:00 | TNXP: HONOR Trial Stopped Early Following Interim Analysis...

2018-07-27 08:55:21 | Benzinga Pro's 5 Stocks To Watch Today

2018-07-27 08:00:00 | Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 HONOR Study of Tonmya® in Military-Related PTSD

2018-07-17 08:10:00 | Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Tonix Pharmaceuticals

2018-07-16 17:23:44 | Why Tonix Pharmaceuticals Stock Soared Today

2018-07-16 13:51:23 | Tonix Shares Surge On Fast Struck Status For Alzheimer's-Related Agitation Candidate